biocatalytic asymmetric synthesis chiral amines ketones applied sitagliptin manufacture
pharmaceutical synthesis can benefit greatly selectivity gains associated enzymatic catalysis report efficient biocatalytic process replace recently implemented rhodium-catalyzed asymmetric enamine hydrogenation large-scale manufacture antidiabetic compound sitagliptin starting enzyme catalytic machinery perform desired chemistry lacked activity toward prositagliptin ketone applied substrate walking modeling mutation approach create transaminase marginal activity synthesis chiral amine variant engineered via directed evolution practical application manufacturing setting resultant biocatalysts showed broad applicability toward synthesis chiral amines previously accessible via resolution work underscores maturation biocatalysis enable efficient economical environmentally benign processes manufacture pharmaceuticals
